AI model AlphaGenome forecasts the consequences of altering every single DNA letter in the human genome.

Science sleuth’s findings raise questions for researchers working to improve the reliability of commercial antibodies.

Pairing NovaSeq X Series software v1.4 with DRAGEN v4.5.4 delivers measurable gains in variant calling accuracy—including in historically difficult-to-resolve regions of the genome. This article dives...

Background Irritable bowel syndrome (IBS) is a complex disorder of gut-brain interaction, with heterogeneous symptoms, no available biomarkers and limited pathogenetic insight. Objective To identify ...

Generating genomic data is only the start. Experts meet virtually to solve complex analysis challenges and share insights with their peers

The two-year study aims to provide diagnoses to unsolved cases through data reanalysis and resequencing with Illumina's TruPath Genome technology.

A major epigenetics study using samples from UK Biobank will unlock new insights into the biological basis of human health and disease.

By acquiring an energy metabolism-related gene via ancient horizontal transfer from a bacterial symbiont, the deep-sea supergiant isopod gains the ability to reprogram its energy allocation, enabling ...

ALT: The Gill Man Waving

YouTube video by passs1302

Meet the members of an Illumina team promoting genomic literacy, generating evidence, and overcoming barriers to testing

Illumina's TruPath™ Genome combines proximity-mapped read technology with DRAGEN™ informatics to unlock comprehensive, haplotype-resolved genomic insights—including phased small variants, structural v...

Illumina placed 80 NovaSeqX sequencers in Q1, driving 1 percent organic revenue growth, and anticipates a similar number of placements in Q2.

Evaluating AI-assisted variant interpretation and shared data networks to potentially impact clinical care

ALT: a man in a blue shirt is sitting in the back seat of a car with his eyes closed .

Despite professional societies and guidelines recommending genetic testing for patients with certain cardiovascular diseases (CVD), genetic testing for CVD remains underutilized in real-world care. Th...

Regeneron Genetics Center (RGC) will join the alliance, while GSK and Amgen will help integrate the proteomic data.

New collaborative initiatives are bringing pharmaceutical R&D together around large-scale datasets to accelerate therapeutic discovery.

Medicaid is doing a novel payment system for the new, promising and expensive sickle cell treatment. It may become a model for all gene therapies being developed.